The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.75
Bid: 7.60
Ask: 7.90
Change: -0.04 (-0.51%)
Spread: 0.30 (3.947%)
Open: 7.90
High: 7.86
Low: 7.75
Prev. Close: 7.90
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Close of Tender Offer

6 Feb 2015 12:21

RNS Number : 2925E
Port Erin Biopharma Investments Ltd
06 February 2015
 





For immediate release

6 February 2015

Port Erin Biopharma Investments Limited

 (the "Company")

Close of Tender Offer

On 13 January 2015, Port Erin Biopharma Investments Limited published and sent to shareholders a circular (the "Circular") setting out the terms of a tender offer in respect of a the Company's interest in the Magna Biopharma Income Fund (the "Tender Offer"). The Record Date for the Tender Offer was 1.00 p.m. on 30 January 2015.

On 2 February 2015, the Company further announced that, following expiry of the Record Date, it had received acceptances in respect of up to 17,164,238 shares ("Eligible Shares") of the Company, representing in aggregate, 50.68 per cent. of the issued share capital.

On 30 January 2015, the Company held 324,174.177 Fund Shares (as defined in the Circular). On 5 February 2015 (the Valuation Date), the aggregate holding of Fund Shares was valued at £3,410,637, representing 62.16 per cent. of the Company's net asset value (adjusted for expenses of the Tender Offer) as at 31 December 2014. The Tender Entitlement (as defined in the Circular) of each shareholder accepting the Tender Offer is accordingly set at 62.16 per cent. of Eligible Shares. Accordingly, on completion of the Tender Offer, the Company will redeem and cancel in aggregate 10,669,278 shares (the "Tender Shares").

On 5 February 2015, the Company completed the sale of 116,635.177 Fund Shares (representing 35.98 per cent. of the Company's total holding of Fund Shares), receiving net proceeds of £1,202,269. Thus, the Tender Price (as defined in the Circular) for each Tender Share (taking into account the expenses of the Tender) shall be £0.1587 (15.87 pence). Shareholders who tendered their holdings will therefore retain approx. 37.84 per cent. of their shareholdings and will receive the Tender Price in respect of their remaining holdings which will be cancelled.

After payment of pro rata costs, Mr Mellon and the Mellon Associates shall, on completion of the Tender Offer, be transferred 46,706 Fund Shares by the Company by way of consideration for the tender of 3,095,563 shares of the Company by Mr Mellon and the Mellon Associates. Pursuant to the Tender, Mr Mellon will have disposed of interests in 3,095,563 Ordinary Shares at the Tender Price and will remain interested in 6,729,273 shares representing 29.01 per cent. of the issued shares.

Following completion of the Tender Offer the Company has a total of 23,195,558 issued shares. The figure of 23,195,558 issued shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company, under the FCA's Disclosure and Transparency Rules.

Timetable following Close of the Tender Offer

Cheques in respect of shareholders' Tender Offer consideration, and their revised certificates for their unsold balance holding of shares will be dispatched by not later than 17 February 2015.

CREST Accounts will be credited with shareholders' Tender Offer consideration, and their revised balance holding of shares by not later than 17 February 2015.

 

 

For further information, please contact:

Port Erin Biopharma Investments Limited

Beaumont Cornish Limited

Peterhouse Capital Limited

The Company

Nomad

Broker

Denham Eke

+44 162 463 9396

Roland Cornish

+44 207 628 3396

Lucy Williams

+44 207 469 0930

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCTFMTTMBBMBPA
Date   Source Headline
12th Apr 20132:17 pmRNSHolding(s) in Company
10th Apr 20137:00 amRNSDirector/PDMR Shareholding
9th Apr 20137:00 amRNSNet Asset Value calculation to 31st March 2013
28th Mar 20137:00 amRNSHalf Yearly Report
8th Feb 20134:50 pmRNSDirector Dealing
8th Feb 20134:45 pmRNSReplacement - Director dealing
30th Jan 20139:55 amRNSDirector Dealing
25th Jan 20133:27 pmRNSNet Asset Value
1st Nov 20127:00 amRNSFinal Results
5th Oct 20122:07 pmRNSNet Asset Value
19th Jul 20123:44 pmRNSDirector/PDMR Shareholding
5th Jul 20121:09 pmRNSNet Asset Value
21st Jun 20127:00 amRNSDirector/PDMR Shareholding
18th Jun 20127:00 amRNSDirector/PDMR Shareholding
13th Jun 20127:00 amRNSDirectorate Change
30th May 201211:40 amRNSDirectorate Change
30th May 201211:14 amRNSHolding(s) in Company
11th Apr 20123:50 pmRNSNet Asset Value
30th Mar 20127:00 amRNSHalf Yearly Report
9th Jan 20123:42 pmRNSNet Asset Value
16th Dec 20114:24 pmRNSChange of Quarterly NAV valuation
20th Oct 20111:46 pmRNSDirector/PDMR Shareholding
14th Oct 20114:43 pmRNSDirector/PDMR Shareholding
14th Oct 201110:53 amRNSInvestment Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.